VRTX Vertex Pharmaceuticals Incorpor

119.92
+1.32  (1%)
Previous Close 118.60
Open 118.10
Price To book 19.68
Market Cap 29.87B
Shares 249,068,000
Volume 1,477,802
Short Ratio 3.45
Av. Daily Volume 1,907,450

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced December 21, 2016. Data due by end of 2017.
CTP-656
Cystic fibrosis
Phase 3 data released March 28, 2017 - primary endpoint met. NDA filing due 3Q 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data due 2H 2017.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data due 2H 2017
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 3 data released March 28, 2017 - primary endpoint met. NDA filing due 3Q 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
Phase 3 data released November 7, 2016 met primary endpoint.
ORKAMBI
Two Copies of the F508del Mutation
Enrollment is expected to be completed in 1H 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation

Latest News

  1. Vertex CEO: Our goal is to have one medicine for all cyst...
  2. Vertex Undergoes FTC Scrubbing for Deal on CF Treatment
  3. Amgen, Gilead, Biogen Won't Lead The Biotech Boom — So Who Will?
  4. Vertex launches college scholarship program for cystic fibrosis patients, families
  5. Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members
  6. Vertex to Present at the UBS Healthcare Conference on May 23
  7. Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion
  8. Zacks.com featured highlights: Covanta Holding, PTC, Etsy, Vertex Pharmaceuticals and Live Nation Entertainment
  9. Vertex Pharmaceuticals' Shares Pop in Afterhours Trading After FDA Approval while AstraZeneca Sinks on Clovis Upgrade
  10. Vertex boosts Kalydeco sales forecast after FDA approves for more patients
  11. Vertex shares up more than 1% after FDA drug approval
  12. FDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations
  13. Love High-Growth? Here Are 3 Stocks to Consider
  14. 5 Toxic Stocks to Steer Clear Of or Play Short Right Now
  15. Why Is Vertex Pharma (VRTX) Stock Soaring This Year?
  16. Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71
  17. 3 Best Stocks in Personalized Medicine
  18. CWALT, Inc. Mortgage Pass-Through Certificates, Series 2006-45T1 -- Moody's Affirms Seven Classes of MSC 2016-UBS11
  19. I Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards
  20. Here's Why Vertex Pharmaceuticals Incorporated Gained 8% in April